Align Technology, Inc. vs Standard Lithium Ltd — how do they compare? Align Technology, Inc. trades at $173.38 (market cap $12.29B), while Standard Lithium Ltd trades at $2.42 (market cap $604.50M). The key difference: Align Technology, Inc. is far larger — about 20.3× Standard Lithium Ltd's market cap, and Align Technology, Inc. is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| ALGN | SLI | |
|---|---|---|
Market Cap | $12.29B | $604.50M |
Sector | Health | Basic Materials |
52-Week High | $197.51 | $5.65 |
52-Week Low | $124.88 | $1.93 |
Enterprise Value | $11.30B | $467.42M |
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $174.63, down 0.8% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with record revenue and clear aligner volume. Fundamentals show solid profitability with a 68.05% gross margin and 9.99% net income margin, though revenue growth has moderated. Recent news highlights a patent win in China and strategic initiatives following activist investor engagement.
The outlook is mixed: analyst consensus is strongly bullish (73% buy ratings), but technicals and slowing revenue growth pose near-term risks. Investment opportunity lies in international expansion and digital dentistry platform growth, while risks include competitive pressures and execution of new strategic initiatives. The stock's valuation at 30x P/E requires sustained earnings growth to justify.
Standard Lithium (SLI) trades at $2.41, down 4.74% on the day, with technical indicators showing a bullish trend despite recent price weakness. The company maintains strong analyst support with 100% buy ratings from 3 analysts, reflecting optimism about its South West Arkansas lithium project development. Recent earnings show improved performance with two consecutive quarterly beats, though the company remains unprofitable with negative ROE and ROA. Institutional interest is growing, with Amundi increasing its stake by 64.9% in Q1 2026 according to SEC filings.
The investment case centers on SLI's transition to production status with major project de-risking events, including a $225M DOE grant and construction contracts. However, significant execution risks remain as the company burns cash with negative operating cash flow. The path to profitability depends on successful project completion and lithium market conditions, creating both substantial upside potential and meaningful downside risk for investors.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →